Intellia Therapeutics Joins Genomics England’s Industry Consortium
January 11 2017 - 4:39PM
Intellia Therapeutics (NASDAQ:NTLA) has joined the Genomics England
Genomics Expert Network for Enterprises (GENE) Consortium, as the
first, dedicated genome editing company to participate in the
100,000 Genomes Project.
The GENE Consortium, established in March 2015, is the 100,000
Genomes Project’s industry partnership. Intellia will join twelve
other companies who are working together in a pre-competitive
trial. The collaboration aims to identify the most effective and
secure way of bringing industry expertise into the 100,000 Genomes
Project to realise future potential benefits for patients affected
by rare diseases or cancers. Members of the consortium are
granted controlled access to aggregated, de-identified genome and
health data of participants. They work alongside experts that
specialise in data analysis, so that the project can benefit from
cutting edge advances in handling Big Data.
Genomics can greatly improve our understanding of health and
disease, unlocking new treatments or repurposing existing
treatments based an individual’s genomic makeup; so-called
personalised medicine.
Sir John Chisholm, Executive Chairman, Genomics England, said:
“The potential for genomics to transform healthcare, from better
diagnoses to new drugs and treatments, is extraordinary. We are
delighted to welcome Intellia Therapeutics to our GENE Consortium.
The UK is a global leader in population sequencing and it’s
important for the future of medicine that we continue to attract
and collaborate with the most innovative emerging technologies in
this space.”
“Access to genomics information is critical as Intellia looks to
better understand the basis of disease and to develop potential
genome-editing treatments,” said Intellia’s Chief Executive Officer
and Founder, Nessan Bermingham, Ph.D., “We look forward to actively
participating in the GENE Consortium, as Genomics England is
enabling scientific exploration and key medical insights that
ultimately will benefit patients.”
About Genomics England
Genomics England is a company owned by
the Department of Health and was set up to deliver the
100,000 Genomes Project. This flagship project will sequence
100,000 whole genomes from National Health Service patients and
their families. Genomics England has four main aims:
- to bring benefit to patients,
- to create an ethical and transparent programme based on
consent,
- to enable new scientific discovery and medical insights,
- to kickstart the development of a UK genomics
industry.
The project is focusing on patients with rare diseases, and
their families, as well as patients with common cancers.
For more information visit our website www.genomicsengland.co.uk
or follow us on Twitter @genomicsengland.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company,
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
permanently editing disease-associated genes in the human body with
a single treatment course. Our combination of deep scientific,
technical and clinical development experience, along with our
leading intellectual property portfolio, puts us in a unique
position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com; Follow us on Twitter @intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Any forward-looking statements in this press release are
based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. For a
discussion of risks and uncertainties, and other important factors,
any of which could cause our actual results to differ from those
contained in the forward-looking statements, see the section
entitled "Risk Factors" in our most recent quarterly report on Form
10-Q filed with the Securities and Exchange Commission, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the Securities and
Exchange Commission. All information in this press release is
as of the date of the release, and Intellia Therapeutics undertakes
no duty to update this information unless required by law.
Intellia Contacts:
Media:
Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 857-706-1071
jenn.smoter@intelliatx.com
Investors:
John Graziano
Trout Group
+ 1 646-378-2942
jgraziano@troutgroup.com
Genomics England Contact:
Katrina Nevin-Ridley
Director of Communications
0207 882 6493
katrina.nevin-ridley@genomicsengland.co.uk
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Sep 2023 to Sep 2024